Citi views the upcoming phase three trial results for AstraZeneca's heart drug Wainua as favorable, expecting positive outcomes that could significantly boost sales. Wainua targets ATTR-cardiomyopathy by suppressing transthyretin protein production, with potential peak sales estimated up to $9 billion if all endpoints are met. A trial failure would slightly reduce valuation but still leave AstraZeneca shares undervalued, suggesting any price dips could be buying opportunities. Results are expected in Q3 2026, making this a critical period for investors to watch.
CelLBxHealth PLC has signed a master services agreement with AstraZeneca, enabling it to provide circulating tumour cell (CTC) analytics for AstraZeneca's drug discovery and development. Using its Parsortix platform, CelLBxHealth will analyze CTCs fr...
T. Rowe Price emphasizes the growing risk of US market concentration in a few mega-cap stocks, now making up 32% of the S&P 500. The firm points to international equities as a promising alternative, noting they trade at a 23% forward P/E discount and...
AstraZeneca, in partnership with Secaro and ERM, is launching a Clean Heat Program to decarbonize industrial heat across its supply chain, aiming to reduce emissions and stabilize costs amid volatile natural gas prices. Industrial heat, a major sourc...
